New preclinical research reports that metformin shields lymphatic vessels from mitochondrial damage caused by 5-fluorouracil and reduces lymphedema in mouse models (ID: e6d9e920130cc98f). The study ties a common diabetes drug to protection of lymphatic function under chemotherapy stress. If translatable, the approach could address a durable on-treatment morbidity problem—chemotherapy-associated lymphatic injury—without changing anticancer dosing in the models. The work also positions mitochondrial damage as a mechanistic lever relevant to lymphedema biology. The findings are not clinical efficacy data, but the mechanistic framing and specific pathology (lymphatic mitochondrial injury) make it a compelling basis for subsequent translational studies.